$AMD(AMD.US)
Is money rotating out of chips, or is the AI trade losing steam?
I’m watching Utilities. AI data centres need enormous amounts of power, making electricity demand a potential long-term growth driver. AI isn’t over, but perhaps the next winners won’t be chipmakers. The money may be moving downstream.
Welcome back! Two of the three local banks reported below forecasts, and chip stocks lost about a trillion US dollars in a single session. Members spent the week separating the headline from the line underneath it. 📊
+1$Coreweave(CRWV.US)
CRWV is a reality check: AI demand is real, but debt is too. The blue sweep adds uncertainty, not the core problem. The real question isn’t whether AI wins, but whether CRWV shareholders do. I’d wait for cash flow, not chase the hype.
Chips just had their worst day since 2020. Here's what drove it, how DBS and OCBC results stack up, and what to watch tonight.
$Jardine Matheson(JMHLY.US)
Jardine Is Selling Its Past — But What Is It Building Next?
What happens when a conglomerate starts selling the businesses investors know it for? Jardine Matheson Southeast Asia is reshaping itself, and the real investment story may only be emerging now.
Fundamentals: The group reduced corporate net debt from US$577 million to US$286 million in 1H2026. Selling its Singapore and Malaysian motor dealerships for approximately S$265 million could further simplify the business, leaving greater emphasis on Astra International and investments in Vietnam.
Valuation: At S$23.70 on 16 October 2026, the shares traded at approximately 7.3 times trailing earnings and 0.41 times book value. However, a conglomerate discount may persist, and headline ratios can be distorted by portfolio changes and special distributions.
Technicals: The share price fell sharply in October and closed below its recent trading range. The S$23.40–24.00 area is a near-term level to watch; reclaiming S$25 would suggest improving momentum. A verified current RSI and moving-average crossover signal are unavailable.
Existing shareholders: Debt reduction and capital returns are encouraging, but monitor the value of the remaining holdings and how proceeds are redeployed.
Prospective investors: A low P/B ratio alone is not enough. Assess the underlying value of Astra and other investments, corporate costs and the price after distributions.
The next test is whether the streamlined portfolio delivers stronger per-share value.
This article is for informational purposes only and does not constitute financial advice.
$Micron Tech(MU.US)
Micron has been sliding since April, even as the Dow rallies on the blues’ convincing congressional win.
The market is betting on a better political outlook, but Micron faces a different test: can AI demand translate into stronger memory prices and profits? That’s what investors need to see before the stock turns.
Democrats swept Congress and the Dow had its best post-midterm day in 44 years, but chipmakers sank as voters turned on AI data centres. At home, DBS missed forecasts, the second big local bank to stu...
$SIA(C6L.SG)
Singapore Airlines (SIA) looks like a case where the good news needs to be viewed with some caution.
The latest move by Air India to cut costs is encouraging. Procurement, maintenance, ground operations and overheads are obvious areas where savings can be made. For SIA, which owns 25.1% of Air India, a successful turnaround would remove a major drag on earnings.
But I wouldn’t call this a turnaround yet.
Air India has already lost heavily and SIA has taken a sizeable hit from its investment. There is also the possibility of further capital being required. That means SIA shareholders could continue funding a business that is still trying to prove it can make money.
The other side of the story is SIA itself. The core business remains profitable and cash-generative, while Scoot provides another growth engine. The recent weakness in reported earnings can also be misleading because of accounting effects and Air India’s losses.
For income investors, the dividend remains an important reason to stay invested. But I would be careful about assuming the recent dividend payout can simply be repeated every year. The ordinary dividend is more sustainable; special dividends should be treated as a bonus rather than an entitlement.
At around the current valuation, I wouldn’t rush to sell everything. If SIA is already a large portfolio position, however, taking some profit makes sense.
My preference would be to keep roughly 70–80% as a core holding and trim 20–30% if the share price provides a good opportunity.
The key thing to watch isn’t another Air India cost-cutting announcement. It is whether Air India’s losses actually narrow.
If they do, SIA could benefit meaningfully. If losses persist and another large capital injection is needed, I would become much more defensive.
UOB stumbled. DBS will emerge as the strongest of the Big 3.
With diversified earnings, strong capital and resilient dividends, DBS has the fundamentals to stand out.
If earnings disappointments trigger a sector-wide pullback, DBS could be best positioned to lead the recovery.
Sometimes, market volatility creates opportunities for quality.
Our three biggest banks report on three consecutive mornings this week — and they go into it off a four-day slide. 🏦$UOB(U11.SG) — Wednesday, before SGX opens$DBS(D05.SG) — Thursday, before SGX opens$...
$UOB(U11.SG)
Is Singapore’s banking rally about to crack?
UOB plunges 5% after missing forecasts. Will DBS and OCBC follow?
With valuations stretched, even decent results may trigger profit-taking. Is a broader correction brewing?
Sometimes, cash and patience are your best defence.
AMD beat forecasts and rose after hours on surging AI chip demand, after chipmakers snapped a three-day slide. At home, UOB's profit missed forecasts and the STI is sliding again, now nearly 10% off i...
$ParkwayLife Reit(C2PU.SG)
Parkway Life REIT: France Expansion — Growth at the Right Price
Parkway Life REIT’s latest French acquisition looks sensible. These are brownfield assets, not greenfield developments — the three nursing homes are already operating and will be leased back to DomusVi for 12 years. That gives Parkway immediate income and avoids construction and ramp-up risks.
The deal is expected to be DPU-accretive, but investors should look beyond that headline. The real question is how much yield Parkway is buying relative to its borrowing cost. Debt funding lifts gearing from 33.8% to around 35.3%. Still comfortable, but it leaves less room for future acquisitions.
France is becoming a meaningful growth market for Parkway. Expanding its French portfolio to 14 properties gives the REIT greater diversification while building on its existing relationship with DomusVi. Long leases and rental escalations also provide useful income visibility.
The concern is price discipline. The acquisition price per bed is higher than Parkway’s previous French purchase, while taxes and transaction costs increase the total investment further. If Parkway keeps paying higher prices for healthcare assets, future acquisitions could become less accretive.
There is also operator, regulatory and currency risk. A 12-year lease sounds attractive, but the income ultimately depends on DomusVi’s ability to remain financially healthy. EUR/SGD movements can also affect Singapore-dollar distributions.
Positioning: Parkway Life remains more suited to investors seeking defensive income and gradual DPU growth rather than a quick capital gain. Existing holders can continue holding, while new investors should avoid chasing the price and wait for a better yield entry point.
The acquisition itself is not the concern. The bigger question is whether Parkway can keep growing without overpaying for assets or stretching its balance sheet.
$Apple(AAPL.US)
Delivered strong earnings, but rising memory costs could pressure margins.
For investors, the real question isn’t revenue growth—it’s whether Apple can protect earnings per share as costs rise.
A beat today doesn’t guarantee a better tomorrow.
Apple beat forecasts but slid after hours as rising memory costs squeeze its margins, while chipmakers fell for a third straight day. At home, the STI is sliding again as the banks lead losses, though...
$Meta Platforms(META.US)
Meta’s Custom AI Chips: A Cost-Saving Opportunity or Another Expensive Bet?
Meta is making a move that could reshape its AI spending. Its MTIA custom chips are designed to power advertising recommendations and AI inference, potentially reducing its reliance on Nvidia.
But investors should look beyond the chip announcements.
The real opportunity is margin expansion.
Meta’s advertising business generates enormous cash flow, but AI infrastructure is becoming increasingly expensive. Developing its own chips gives Meta greater control over computing costs, hardware design and supplier negotiations.
If MTIA can deliver comparable performance at a lower cost for specific workloads, the savings could become meaningful at scale. That is money potentially retained within Meta rather than flowing to external chip suppliers.
However, this is not a straightforward Nvidia replacement story.
Meta still depends on external partners for manufacturing, advanced packaging and high-bandwidth memory. Nvidia remains important for more complex AI workloads, where its ecosystem and software capabilities are difficult to replicate.
The investment question is whether the savings justify the spending.
Building custom silicon and expanding data centres require substantial upfront capital. Investors need to watch whether these investments translate into stronger operating margins, sustainable free cash flow and better returns on invested capital.
For now, Meta’s custom chips represent a strategic advantage worth watching, not a guaranteed financial win.
The opportunity is clear: more control, lower costs and greater flexibility.
But the proof will come through the numbers, not the announcements.
FaithAnchor’s takeaway: The strongest businesses do not need to own everything. They need to know where ownership creates value and where paying others makes more sense.
Not financial advice.
$Moderna(MRNA.US)
Moderna Has Soared. Is Its Cancer Vaccine Worth the Premium?
Moderna $Moderna(MRNA.US) is reinventing itself beyond COVID-19 vaccines. Its personalised melanoma vaccine, developed with Merck, delivered encouraging Phase 3 results, opening a potential new growth chapter. But after a spectacular rally, investors must ask whether the opportunity justifies the price.
Fundamentals: progress, but losses persist
Moderna reported Q2 2026 revenue of US$145 million and a net loss of US$782 million. Management expects FY2026 revenue growth of up to 10%, with year-end cash projected at US$4.7–5.2 billion. The cancer vaccine could diversify revenue, but regulatory approval, manufacturing costs and commercial uptake remain key hurdles.
Valuation: the biggest concern
At around 32 times trailing sales, Moderna commands a demanding valuation despite continued losses. Traditional price-to-earnings comparisons are unhelpful while earnings remain negative. The market is effectively pricing in substantial future success from its pipeline. Any delay or disappointing commercial outlook could trigger a sharp correction.
How should investors position themselves?
New investors should avoid chasing the rally and consider staged entry only if valuation and risk/reward improve. Existing holders may consider partial profit-taking if the position has grown disproportionately. Long-term investors should monitor regulatory progress, cash burn and evidence of sustainable revenue growth.
Verdict: Moderna’s cancer vaccine offers genuine potential, but scientific success is not the same as investment success. The business needs to convert clinical progress into durable earnings before its valuation becomes easier to justify.
$SK Hynix(SKHY.US)
SK Hynix vs Seagate: Both Beat Earnings. One Flew, One Fell.
SK Hynix surged on explosive earnings, 80% operating margins and booming HBM demand.
Seagate beat earnings too, but slowing shipment growth and sky-high expectations took the shine off.
Same AI party, different expectations at the door.
The lesson? Beating earnings is good. Beating expectations is better.
FaithAnchor — Stay grounded. Stay the course.
Welcome back! Earnings week landed all at once, and members spent it asking which line of each report the market was actually reading. 📊
$Alphabet(GOOGL.US)
A brutal day for Alphabet. A 12% drop is not something investors can simply brush aside. But does one bad day change the long-term story? I would be more concerned about rising AI spending and whether future returns can justify the cost. Stay the course, but don’t stop questioning what you own.
Alphabet had its worst day ever, and Amazon and Intel slid after hours. Eli Lilly and Apple bucked the selloff with records. Let's dig in 👇 💬 Big Tech is paying for AI with cash flow. Buying the Alpha...
$DFIRG USD(D01.SG)
DFI Retail’s Starbucks Bet: Strategic Upgrade or an Expensive Cup of Coffee?
DFI Retail Group’s decision to swap its 50% stake in Maxim’s Caterers for full operational control of its regional Starbucks business marks a major shift in strategy. Alongside a US$340 million cash payment, the deal raises a crucial question: is DFI buying a stronger growth engine or taking on more risk from a global coffee brand facing challenges?
The business generated nearly US$750 million in revenue in 2025, with a 7% operating margin. DFI aims to grow annual revenue to US$900 million by 2028 and achieve a medium-term operating margin of 8–9%.
The opportunity is clear: greater control over operations, procurement, marketing and store expansion. DFI could also leverage its existing retail network to improve site selection and customer insights.
Is Starbucks losing its appeal?
Customer preferences are changing. Convenience, mobile ordering, affordability and value increasingly matter alongside the premium café experience. Starbucks must convince customers that its coffee and experience justify the price, especially when cheaper alternatives are readily available.
Across Southeast Asia, growing urban populations and established café cultures offer opportunities. Yet local tastes, purchasing power and intense competition mean the American playbook cannot simply be replicated everywhere.
How should investors position themselves?
DFI’s bet makes strategic sense if it can turn greater operational control into better margins and sustainable cash flow. Its target of US$900 million in revenue and 8–9% margins is worth monitoring, but execution matters more than ambition.
Bottom line: DFI is betting that it can run Starbucks better, not that coffee will suddenly become more popular. The opportunity is real, but shareholders need proof that more control will deliver more profit.
$StarHub(CC3.SG)
Singapore Telcos: Is Consolidation the Next Investment Opportunity?
For StarHub, the acquisition brings more customers, but the real test is whether they translate into sustainable earnings. With mobile plans competing aggressively on price, subscriber growth alone is not enough. Investors should watch customer retention, integration costs and profit margins.
Singtel remains the more diversified option. Beyond mobile services, it has exposure to regional associates, digital services and data-centre infrastructure. These businesses offer additional growth drivers, although investors should distinguish recurring earnings from one-off gains and special dividends.
StarHub offers a more direct play on consolidation and operational improvements. Its enterprise business and cost-saving initiatives could support a recovery, but investors need to see stronger earnings before assuming the turnaround is on track.
Keppel, meanwhile, offers indirect exposure to M1 through its broader portfolio. Any restructuring could unlock value, but a potential sale remains uncertain.
For long-term investors, Singtel deserves closer attention for its diversified earnings and regional exposure. StarHub may appeal to those willing to take on more execution risk in exchange for potential upside.
The MyRepublic deal is not a game changer. The bigger opportunity lies in whether Singapore’s telcos can turn consolidation into better margins, stronger cash flow and sustainable dividends.
The investment approach: Focus on earnings quality and valuation rather than subscriber numbers or takeover speculation. Even a good business can be a poor investment if the price is too high.
For discussion purposes only. Not financial advice.
$Mapletree Ind Trust(ME8U.SG)
ME8U: A Blue Chip, But At What Cost?
A blue-chip REIT can still lose its shine when the fundamentals turn.
ME8U’s 6.6% DPU decline is a reminder that reputation alone cannot protect distributions. With US leasing under pressure, management needs to rethink where the next dollar of growth comes from.
I would look towards Japan and Singapore’s data-centre markets, but only where tenant demand and returns justify the investment. Equally important is cutting exposure to weaker assets without sacrificing long-term value.
For investors, the question is simple: is this a temporary setback or a structural problem?
Not financial advice.
SK Hynix says its memory chips are sold out until 2029, and every stock in the chip index rose for a second day. Tonight Microsoft and Alphabet report, just before the Fed. Let's dig in 👇💬 SK Hynix is...
